DoubleLine ETF Adviser LP Invests $1.55 Million in Kenvue Inc. $KVUE

DoubleLine ETF Adviser LP bought a new position in shares of Kenvue Inc. (NYSE:KVUE) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 95,548 shares of the company’s stock, valued at approximately $1,551,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Savant Capital LLC grew its stake in Kenvue by 9.1% during the second quarter. Savant Capital LLC now owns 21,845 shares of the company’s stock worth $457,000 after buying an additional 1,826 shares during the last quarter. AE Wealth Management LLC boosted its holdings in shares of Kenvue by 47.7% in the 2nd quarter. AE Wealth Management LLC now owns 23,428 shares of the company’s stock worth $490,000 after acquiring an additional 7,571 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Kenvue by 152.2% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,203 shares of the company’s stock worth $1,532,000 after acquiring an additional 44,173 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Kenvue during the 2nd quarter worth approximately $254,000. Finally, Vise Technologies Inc. acquired a new stake in Kenvue during the 2nd quarter valued at $329,000. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on KVUE shares. Citigroup boosted their price objective on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. Barclays upped their price target on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Friday, March 6th. Jefferies Financial Group lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $23.00 to $18.00 in a report on Friday, January 30th. Finally, Canaccord Genuity Group raised their price objective on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. Three analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Price Performance

Shares of KVUE stock opened at $17.51 on Friday. The firm has a market cap of $33.55 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 3.97 and a beta of 0.51. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $17.89 and a 200 day moving average price of $17.30.

Kenvue (NYSE:KVUE) last released its earnings results on Tuesday, February 17th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. The company had revenue of $3.78 billion for the quarter, compared to the consensus estimate of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.72%. The company’s revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 EPS. Research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th were paid a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. Kenvue’s payout ratio is 107.79%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.